Biologics Coverage

Pediatric Vaccine Market Definition

Pediatric vaccines are immunizations specifically designed to protect children from various infectious diseases. These vaccines are administered during infancy and childhood from birth till 18 years. Moreover, these vaccines stimulate the immune system to recognize and combat pathogens, thereby preventing illnesses such as measles, mumps, rubella, polio and hepatitis. The pediatric vaccine market consists of sales, by entities (organizations, sole traders and partnerships), of pediatric vaccine that are used by healthcare providers, including pediatricians, family physicians and public health clinics, who administer these vaccines according to established immunization schedules. Parents and guardians are also key stakeholders, ensuring their children receive timely vaccinations. Pediatric vaccines are typically administered during routine healthcare visits, starting from birth and continuing through adolescence, following schedules recommended by health authorities.

Monoclonal Antibodies (MAs) Market Definition

Monoclonal antibodies (MABS) refer to laboratory-produced proteins intended to boost your immune system. Treatments for monoclonal antibodies are often administered as IV solutions, frequently in an infusion center. Antibodies are a component of your immune system. To kill them, they seek out the antigens (foreign substances) and adhere to them. The main types of sources of monoclonal antibodies (MABS) are murine, chimeric, humanized, and human. A murine antibody has two types of chains, one of which is from a mouse and the other from a human. The pre-stem-o- in the INN of a murine antibody is used to identify it. It is used in anti-cancer, immunological, anti-infective monoclonal antibodies (MAbs), neuropharmacological, cardiovascular, cerebrovascular, and other applications and is implemented in various sectors such as hospitals, private clinics, and research institutes.

Monoclonal Antibodies (MAs) Market Segmentation

The monoclonal antibodies (MAbs) market covered in this report is segmented – 1) By Source: Murine, Chimeric, Humanized, Human 2) By Application: Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAs), Neuropharmacological, Cardiovascular And Cerebrovascular, Other Applications 3) By End Users: Hospitals, Private Clinics, Research Institute Subsegments: 1) By Murine: Fully Murine MAbs, Murine-Derived MAbs 2) By Chimeric: Chimeric MAbs With Murine Variable Regions, Chimeric MAbs With Human Constant Regions 3) By Humanized: Humanized MAbs With Minor Murine Components, Fully Humanized MAbs 4) By Human: Fully Human MAbs, Engineered Human MAbs

Therapeutic Proteins Market Definition

Therapeutic proteins refer to pharmaceuticals that are genetically modified versions of human proteins that are found naturally. These powerful, quick-acting medications were developed in a lab for pharmaceutical usage. Therapeutic proteins have altered how diseases are treated since they are very effective in vivo. The main types of products in therapeutic proteins market are insulin, fusion proteins, erythropoietin, interferon, human growth hormone, and follicle-stimulating hormone. Insulin is a peptide hormone produced by beta cells in the pancreatic cells that serves as the individual's primary anabolic hormone. It affects fat, carbohydrate, and protein metabolism by boosting glucose uptake from the blood into the fat, liver, and skeletal muscle cells. The different functions include enzymatic and regulatory activity, special targeting activity, vaccines, and protein diagnostics and are used in various applications such as metabolic disorders, immunologic disorders, hematological disorders, cancer, hormonal disorders, genetic disorders, and others.

Therapeutic Proteins Market Segmentation

The therapeutic proteins market covered in this report is segmented – 1) By Product Type: Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, follicle stimulating hormone 2) By Function: Enzymatic And Regulatory Activity, Special Targeting Activity, Vaccines, Protein Diagnostics 3) By Application: Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders, Other Applications Subsegments: 1) By Insulin: Rapid-Acting Insulin, Short-Acting Insulin, Intermediate-Acting Insulin, Long-Acting Insulin 2) By Fusion Protein: Tnf-Alpha Inhibitors, Anti-Cd20 Fusion Proteins, Other Targeted Fusion Proteins 3) By Erythropoietin: Epoetin Alpha, Darbepoetin Alfa, Other Erythropoietin Variants 4) By Interferon: Interferon Alpha, Interferon Beta, Interferon Gamma 5) By Human Growth Hormone: Somatropin, Somatrem 6) By Follicle Stimulating Hormone: Follitropin Alpha, Follitropin Beta

Digestive Enzymes Market Definition

Digestive enzymes refer to compounds that aid in digestion by assisting with food breakdown. These proteins accelerate the chemical processes that transform food into compounds that can be absorbed by the digestive system. The salivary glands and the cells lining the stomach, pancreas, and small intestine produce (release) them. The main types of digestive enzymes are carbohydrates, protease, lipase, and other enzyme types. Lipase is a protein produced by the pancreas, a small organ located near the stomach that aids in fat digestion. The enzymes originated from animals, fungi, microbial, and plants that are used for indigestion, chronic pancreatitis, irritable bowel syndrome, and other applications. The various distribution channel includes retail stores and online stores.

Digestive Enzymes Market Segmentation

The digestive enzymes market covered in this report is segmented – 1) By Enzyme Type: Carbohydrates, Protease, Lipase, Other Enzyme Types 2) By Origin: Animal, Fungi, Microbial, Plant 3) By Application: Indigestion, Chronic Pancreatitis, Irritable Bowel Syndrome, Other Applications 4) By Distribution Channel: Retail Stores, Online Stores Subsegments: 1) By Carbohydrates: Amylase, Alpha-Galactosidase, Lactase, Sucrase, Maltase 2) By Protease: Pepsin, Trypsin, Chymotrypsin, Bromelain, Papain 3) By Lipase: Pancreatic Lipase, Gastric Lipase, Lingual Lipase 4) By Other Enzyme Types: cellulase, Lactase, Phytase, Beta-Glucanase, Xylanase

Oncology Biosimilars Market Definition

Oncology biosimilars refer to biologically similar drugs or medications that are physiologically comparable to biological cancer treatments. Infection risk is increased by decreased white blood cell counts, which can be treated as a side effect of cancer therapy. The main drug types of oncology biosimilars are monoclonal antibodies, immunomodulators, hematopoietic agents, and granulocyte colony-stimulating factor (G-CSF). Immunomodulators are a class of drugs that primarily target pathways involved in the treatment of multiple myeloma and a few other cancers. The types of cancer treated include breast cancer, colorectal cancer, blood cancer, neutropenia cancer, and non-small cell lung cancer, and the various distribution channels involved are hospital pharmacies, retail pharmacies, and online pharmacies.

Oncology Biosimilars Market Segmentation

The oncology biosimilars market covered in this report is segmented – 1) By Drug Type: Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF) 2) By Cancer Type: Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types 3) By Distribution Type: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy Subsegments: 1) By Monoclonal Antibody: rituximab biosimilars, Trastuzumab Biosimilars, bevacizumab biosimilars, Pembrolizumab Biosimilars 2) By Immunomodulators: Thalidomide Biosimilars, Lenalidomide Biosimilars, Pomalidomide Biosimilars 3) By Hematopoietic Agents: Epoetin Biosimilars, Darbepoetin Biosimilars 4) By Granulocyte Colony-Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars

Interferons Market Definition

Interferons refer to a natural substance that supports the body's immune system in the battle against illness, including cancer. White blood cells and other cells in the body produce interferons, but they can also be produced in a lab for use in treating various disorders. The main types of interferons are interferon alpha, interferon beta, and interferon-gamma. Interferon alpha is a cytokine generated by the innate immune system in response to environmental exposures, including viral infections. The products are distributed by hospital pharmacies, online pharmacies, retail pharmacies, and others and are used for the treatment of Hepatitis B, hepatitis c, melanoma, leukemia, multiple sclerosis, and renal cell carcinoma.

Interferons Market Segmentation

The interferons market covered in this report is segmented – 1) By Type: Interferon Alpha, Interferon Beta, Interferon Gamma 2) By Application: Hepatitis B, Hepatitis C, Melanoma, Leukemia, Multiple Sclerosis, Renal Cell Carcinoma 3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Other Distribution Channels Subsegments: 1) By Interferon Alpha: Interferon Alpha-2a, Interferon Alpha-2b 2) By Interferon Beta: Interferon Beta-1a, Interferon Beta-1b 3) By Interferon Gamma: Interferon Gamma-1b

Protein Inhibitors Market Definition

Protein inhibitors refer to compounds that interfere with the steps directly involved in the production of new proteins in cells. Protein inhibitors operate at the ribosome level, benefiting from the significant variations between prokaryotic and eukaryotic ribosome architectures. The main product types of protein inhibitors are protein kinase inhibitors, monoclonal antibodies, and others. Monoclonal antibodies are laboratory-created molecules designed to act as substitute antibodies, restoring, enhancing, modifying, or mimicking the immune system's attack on unwanted cells, such as cancer cells. The protein inhibitors are used in the treatment of oncology, inflammatory diseases, and others, and are distributed by hospital pharmacies, independent pharmacies, and online pharmacies.

Protein Inhibitors Market Segmentation

The protein inhibitors market covered in this report is segmented – 1) By Product: Protein Kinase Inhibitors, Monoclonal Antibody, Other Products 2) By Application: Oncology, Inflammatory Diseases, Other Applications 3) By Distribution Channel: Hospital Pharmacies, Independent Pharmacies, Online Pharmacies Subsegments: 1) By Protein Kinase Inhibitors: Selective Kinase Inhibitors, Non-selective Kinase Inhibitors, Small Molecule Kinase Inhibitors, Biologic Kinase Inhibitors 2) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies, Conjugated Monoclonal Antibodies 3) By Other Products: Peptide Inhibitors, Protein Degradation Technologies, Small Molecule Inhibitors, Combination Therapy Products

Cellular Immunotherapy Market Definition

Cellular immunotherapy refers to a sort of immunotherapy in which a patient receives T cells, an immune cell, to aid the body in fighting diseases like cancer. It is a cutting-edge kind of treatment that uses the body's immune system to combat cancer. The main therapies of cellular immunotherapy are tumor-infiltrating lymphocyte (TIL) therapy, Engineered T Cell Receptor (TCR) Therapy, chimeric antigen receptor (CAR) T cell therapy, and natural killer (NK) cell therapy. Tumor-infiltrating lymphocyte (TIL) therapy is a type of adoptive cellular therapy that involves extracting infiltrated lymphocytes from tumors, culturing and amplifying them in vitro, and then infusing them back into patients to treat them. The various primary indications include b-cell malignancies, prostate cancer, renal cell carcinoma, liver cancer, non-Hodgkin lymphoma, and others, and are used for the treatment of prostate cancer, breast cancer, skin cancer, ovarian cancer, brain tumors, lung cancer, and others.

Cellular Immunotherapy Market Segmentation

The cellular immunotherapy market covered in this report is segmented – 1) By Therapy: Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy 2) By Primary Indication: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications 3) By Application: Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer, Other Applications Subsegments: 1) By Tumour-Infiltrating Lymphocyte (TIL) Therapy: Autologous TIL Therapy, Allogeneic TIL Therapy, Other TIL Therapy 2) By Engineered T Cell Receptor (TCR) Therapy: Alpha-Beta TCR Therapy, Gamma-Delta TCR Therapy, Other Engineered TCR Therapy 3) By Chimeric Antigen Receptor (CAR) T Cell Therapy: Autologous CAR T Cell Therapy, Allogeneic CAR T Cell Therapy, CAR T Cell Therapy For Solid Tumors, CAR T Cell Therapy For Hematologic Malignancies, Other CAR T Cell Therapy 4) By Natural Killer (NK) Cell Therapy: Autologous NK Cell Therapy, Allogeneic NK Cell Therapy, NK Cell Therapy With Engineered Modifications, Other NK Cell Therapy